

## AMENDMENTS TO THE CLAIMS

1 to 33. (Canceled).

34. (New) A compound defined by the Formula:



wherein AA in said Formula corresponds to an amino acid sequence selected from the group consisting of:

His-Gln-Lys-Leu-Val-Phe;

His-His-Gln-Lys-Leu-Val-Phe-Phe-Ala-Glu;

His-His-Gln-Lys-Leu-Val-Phe;

Val-His-His-Gln-Lys-Leu-Val-Phe-Phe-Ala;

Val-His-His-Gln-Lys-Leu-Val-Phe;

Tyr-Glu-Val-His-His-Gln-Lys-Leu-Val-Phe; and

Gly-Tyr-Glu-Val-His-His-Gln-Lys-Leu-Val;

and wherein

R<sub>1</sub> is H or –CO-R<sub>3</sub> bonded at the α-amino group of the N-terminal of AA;

R<sub>2</sub> is H or –OR<sub>4</sub> or NR<sub>5</sub>R<sub>6</sub> all bound to the α-carboxyl group of the α-carboxyterminal of AA;

R<sub>3</sub> is a straight or branched carbon chain of 1-4 carbon atoms;

R<sub>4</sub> is a straight or branched carbon chain of 1-4 carbon atoms;

R<sub>5</sub> and R<sub>6</sub> independently are H, alkyl, cycloalkyl, aryl or substituted aryl or together are –(CH<sub>2</sub>)<sub>n</sub>–, where n is 4-5;

R<sub>1</sub> and R<sub>2</sub> together can form a hydrocarbon ring or heterocyclic ring; and  
said amino acids can be either D- or L-isomers.

35. (New) A peptide which consists of a chemically synthesized amino acid sequence that is selected from the group consisting of:

His-Gln-Lys-Leu-Val-Phe;

Val-His-His-Gln-Lys-Leu-Val-Phe-Phe-Ala;  
Val-His-His-Gln-Lys-Leu-Val-Phe;  
Tyr-Glu-Val-His-His-Gln-Lys-Leu-Val-Phe; and  
Gly-Tyr-Glu-Val-His-His-Gln-Lys-Leu-Val.

36. (New) A composition, comprising the compound of claim 34 and a pharmaceutically acceptable carrier or excipient.
37. (New) A composition, comprising the peptide of claim 35 and a pharmaceutically acceptable carrier or excipient.
38. (New) A method for treating or preventing Alzheimer's disease or another disease characterized by amyloidosis in a patient in need thereof, comprising administering to said patient a therapeutic effective amount of the composition of claim 36.
39. (New) A method for treating or preventing Alzheimer's disease or another disease characterized by amyloidosis in a patient in need thereof, comprising administering to said patient a therapeutic effective amount of the composition of claim 37.
40. (New) A method for treating or preventing Alzheimer's disease in a patient in need thereof, comprising administering to said patient a therapeutic effective amount of the composition of claim 36.
41. (New) A method for treating or preventing Alzheimer's disease in a patient in need thereof, comprising administering to said patient a therapeutic effective amount of the composition of claim 37.